{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=79",
    "query": {
      "intervention": "Sequence",
      "page": 79
    },
    "page_size": 10
  },
  "pagination": {
    "page": 79,
    "page_size": 10,
    "total_count": 2516,
    "total_pages": 252,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=80&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequence&page=78&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T04:28:45.135Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01635348",
      "title": "Thinking, Walking Outcomes by Type of Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gait Disorder, Sensorimotor",
        "Cognitive Disorder"
      ],
      "interventions": [
        {
          "name": "motor skill gait exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "aerobic gait intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-01",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2015-07-30",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01635348"
    },
    {
      "nct_id": "NCT03811847",
      "title": "A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer Dementia"
      ],
      "interventions": [
        {
          "name": "Methylphenidate Extended Release Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "55 Years to 95 Years"
      },
      "enrollment_count": 11,
      "start_date": "2019-11-01",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2023-06-02",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Charlestown, Massachusetts",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03811847"
    },
    {
      "nct_id": "NCT02648438",
      "title": "A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "AZD7594 Solution for infusion (150 μg intravenous formulation)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 Oral suspension (1200 μg oral formulation)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 Pressurized inhalation suspension (400 μg) by pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2016-01-12",
      "completion_date": "2016-06-01",
      "has_results": true,
      "last_update_posted_date": "2017-06-15",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02648438"
    },
    {
      "nct_id": "NCT00683852",
      "title": "A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole 5mg",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole 2mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 225,
      "start_date": "2008-09",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2017-07-19",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00683852"
    },
    {
      "nct_id": "NCT07578636",
      "title": "A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Male Volunteers"
      ],
      "interventions": [
        {
          "name": "Oral [14C] PF-07799544",
          "type": "DRUG"
        },
        {
          "name": "Oral Unlabeled PF-07799544",
          "type": "DRUG"
        },
        {
          "name": "IV [14C] PF-07799544",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2026-05-18",
      "completion_date": "2026-08-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07578636"
    },
    {
      "nct_id": "NCT00463814",
      "title": "AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "AZD6244",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 58,
      "start_date": "2007-03-08",
      "completion_date": "2027-03-26",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00463814"
    },
    {
      "nct_id": "NCT04580979",
      "title": "Natural History Study of FDXR Mutation-related Mitochondriopathy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurodegenerative Disease, Hereditary",
        "Mitochondrial Diseases",
        "Optic Atrophy"
      ],
      "interventions": [
        {
          "name": "Mutation analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "0 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2020-11-03",
      "completion_date": "2023-08-17",
      "has_results": false,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04580979"
    },
    {
      "nct_id": "NCT01639729",
      "title": "Effect of Delivery Route on PK of Sufentanil NanoTab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Treatment A: Sufentanil IV",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: Sufentanil NanoTab Sublingual",
          "type": "DRUG"
        },
        {
          "name": "Treatment C: Sufentanil NanoTab Buccal",
          "type": "DRUG"
        },
        {
          "name": "Treatment D: Sufentanil NanoTab Oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Talphera, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 25,
      "start_date": "2012-07",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2015-10-01",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01639729"
    },
    {
      "nct_id": "NCT04373031",
      "title": "Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "IRX 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-12-30",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04373031"
    },
    {
      "nct_id": "NCT02236286",
      "title": "Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-09",
      "completion_date": "2018-10",
      "has_results": false,
      "last_update_posted_date": "2018-10-30",
      "last_synced_at": "2026-11-14T04:28:45.135Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02236286"
    }
  ]
}